Loading company…
Oisin Biotechnologies develops genetic medicines for age-related conditions using a non-viral delivery system.
Founded in 2014 and based in Seattle, US, Oisin Biotechnologies develops genetic therapies for conditions related to aging. Its Fusogenix™ Proteo-Lipid Vehicle delivers DNA and RNA payloads, and its pipeline targets frailty, muscle growth, fat cell elimination, and senescent cell removal. The company raised USD 5.38 mn in Series A funding led by AbbVie Biotech Ventures.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in